Table 1.
Baseline characteristics of all men with prostate cancer, men with prostate cancer stratified by treatment, and the matched prostate cancer‐free men (no prostate cancer)
| No prostate cancer n = 121 018 | Prostate cancer n = 25 967 | WW n = 7209 | Primary AAs n = 3368 | Primary GnRH agonists n = 6982 | Primary orchiectomy n = 705 | ADT as a result of disease progression n = 7703 | |
|---|---|---|---|---|---|---|---|
| Follow up time, years, mean ( sd ) | 4.5 (2.2) | 4.2 (2.2) | 4.6 (2.2) | 4.2 (2.1) | 3.9 (2.3) | 3.4 (2.2) | 4.2 (2.2) |
| Age at inclusion, years, mean ( sd ) | 76.2 (7.6) | 76.5 (7.6) | 76.3 (7.1) | 76.9 (6.5) | 78.4 (7.3) | 81.6 (5.9) | 74.1 (8.1) |
| Age at inclusion, n (%) | |||||||
| <65 years | 10 232 (8.5) | 2086 (8.0) | 503 (7.0) | 168 (5.0) | 338 (4.8) | 7 (1.0) | 1070 (13.9) |
| 65–74 years | 38 488 (31.8) | 8009 (30.8) | 2310 (32.0) | 977 (29.0) | 1649 (23.6) | 88 (12.5) | 2985 (38.8) |
| 75–79 years | 32 891 (27.2) | 6944 (26.7) | 2056 (28.5) | 1163 (34.5) | 1872 (26.8) | 148 (21.0) | 1705 (22.1) |
| 80–84 years | 25 803 (21.3) | 5724 (22.0) | 1653 (22.9) | 739 (21.9) | 1851 (26.5) | 253 (35.9) | 1228 (15.9) |
| 85 years | 13 604 (11.2) | 3204 (12.3) | 687 (9.5) | 321 (9.5) | 1272 (18.2) | 209 (29.6) | 715 (9.3) |
| CCI at inclusion, n (%) | |||||||
| 0 | 73 912 (61.1) | 15 358 (59.1) | 4422 (61.3) | 1985 (58.9) | 3825 (54.8) | 346 (49.1) | 4780 (62.1) |
| 1 | 22 234 (18.4) | 5131 (19.8) | 1343 (18.6) | 688 (20.4) | 1432 (20.5) | 178 (25.2) | 1490 (19.3) |
| 2 | 13 189 (10.9) | 3056 (11.8) | 845 (11.7) | 381 (11.3) | 927 (13.3) | 103 (14.6) | 800 (10.4) |
| 3+ | 11 683 (9.7) | 2422 (9.3) | 599 (8.3) | 314 (9.3) | 798 (11.4) | 78 (11.1) | 633 (8.2) |
| Year of follow up start, n (%) | |||||||
| 2006–2008 | 53 451 (44.2) | 11 444 (44.1) | 3107 (43.1) | 1169 (34.7) | 3397 (48.7) | 395 (56.0) | 3376 (43.8) |
| 2009–2010 | 35 820 (29.6) | 7673 (29.5) | 2292 (31.8) | 1035 (30.7) | 1998 (28.6) | 208 (29.5) | 2140 (27.8) |
| 2011–2012 | 31 747 (26.2) | 6850 (26.4) | 1810 (25.1) | 1164 (34.6) | 1587 (22.7) | 102 (14.5) | 2187 (28.4) |
| Prostate cancer risk category*, n (%) | |||||||
| No prostate cancer | 121 018 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Low risk | 0 (0.0) | 3430 (13.2) | 1586 (22.0) | 140 (4.2) | 154 (2.2) | 4 (0.6) | 1546 (20.1) |
| Intermediate risk | 0 (0.0) | 7436 (28.6) | 2742 (38.0) | 795 (23.6) | 1041 (14.9) | 91 (12.9) | 2767 (35.9) |
| High risk | 0 (0.0) | 10 618 (40.9) | 1889 (26.2) | 1794 (53.3) | 3823 (54.8) | 383 (54.3) | 2729 (35.4) |
| Regionally metastatic | 0 (0.0) | 3489 (13.4) | 229 (3.2) | 605 (18.0) | 1900 (27.2) | 223 (31.6) | 532 (6.9) |
| Missing data | 0 (0.0) | 994 (3.8) | 763 (10.6) | 34 (1.0) | 64 (0.9) | 4 (0.6) | 129 (1.7) |
| Educational level, n (%) | |||||||
| Low | 56 131 (46.4) | 11 918 (45.9) | 3308 (45.9) | 1514 (45.0) | 3618 (51.8) | 430 (61.0) | 3048 (39.6) |
| Middle | 41 003 (33.9) | 9123 (35.1) | 2556 (35.5) | 1181 (35.1) | 2290 (32.8) | 188 (26.7) | 2908 (37.8) |
| High | 21 456 (17.7) | 4646 (17.9) | 1266 (17.6) | 637 (18.9) | 976 (14.0) | 74 (10.5) | 1693 (22.0) |
| Missing | 2428 (2.0) | 280 (1.1) | 79 (1.1) | 36 (1.1) | 98 (1.4) | 13 (1.8) | 54 (0.7) |
| Marital status, n (%) | |||||||
| Married | 78 413 (64.8) | 17 382 (66.9) | 4716 (65.4) | 2248 (66.7) | 4357 (62.4) | 411 (58.3) | 5650 (73.3) |
| Not married | 42 605 (35.2) | 8585 (33.1) | 2493 (34.6) | 1120 (33.3) | 2625 (37.6) | 294 (41.7) | 2053 (26.7) |
AA, antiandrogen; ADT, androgen deprivation therapy; CCI, Charlson comorbidity index; WW, watchful waiting. *Modified National Comprehensive Cancer Network classification.